Biotech.
Company
- Reports this week
- 1
- Active events
- 2
- Connections
- 51
What's happening
Active this week
-
Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.Some support3 reports1 development inside
-
The biotech industry is set to develop new plastics and fuels, and Google AI is predicting future population trends.Some support1 report
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Amgen is classified as biotech for legacy reasons, a classification influenced by past failures experienced in London.Some support1 report
-
The SEC legally requires fiduciaries to prioritize client interests, while specific ETFs like XBI offer equal-weighted exposure to biotech and hedge against AI concentration risk.Some support2 reports
-
M&A activity is driving sector recovery.Some support1 report1 development inside
-
Structure Therapeutics is an early-stage business operating within the biotech sector.Speculative1 report
-
Gains in Big Tech shares fueled market rise, while biotech company Enveda reached a billion-dollar valuation and a new international equity ETF was launched.Some support1 report
-
EIT Food is discussing the shift towards biotech-driven approaches to address climate change impacts on Arabica coffee yields.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Biotech
Events traced to Biotech, step by step, newest firstAround Biotech this week
News at the entities that move Biotech most-
FDA StructuralChris Carr, Georgia Attorney General, seeks stricter state laws following FDA warnings about kratom.Moves Biotech
-
Federal Trade Commission StructuralA report tracks the Federal Trade Commission's failure to enforce antitrust laws.Moves Biotech
-
Massachusetts StructuralThe Haitian Mental Health Network was hosted at William James College in Massachusetts.Moves Biotech
-
Martin Shkreli OperationalRZA and Cilvaringz's collaboration led to a new album, while RZA recalled escaping a past album deal with Martin Shkreli.Moves Biotech
-
Goldman Sachs Mentioned togetherGoldman Sachs granted funding to Every Cure, and Asahi Pompey was named head of the Goldman Sachs Foundation.Moves Biotech
-
State Street OperationalFed policy shifts and high bond yields are impacting market sentiment, causing CoreWeave stock to plunge and State Street ETFs to track specific sectors.Moves Biotech
Connections
The 25 strongest of 51, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA functions as the essential regulatory gatekeeper whose approvals and delays dictate the market viability of biotech companies.
-
Martin Shkreli Operational
Martin Shkreli actively trades and comments on biotech stocks.
-
State Street Operational
State Street provides management services for exchange-traded funds focused on the biotech sector.
-
Federal Trade Commission Structural
The Federal Trade Commission regulates the biotech industry regarding drug industry violations.
-
ICON plc Operational
Both companies operate within the same Pharma/Biotech market segment, indicating active market interaction and potential competition.
-
Massachusetts Structural
Massachusetts state tax laws structurally impact the R&D incentives of biotech companies.
-
EIT Food Structural
one depends on the other
-
Vertex Pharmaceuticals Shared context
Vertex Pharmaceuticals is identified as a major holding within the broader biotech sector ETF.
Show all 25 connections
-
Goldman Sachs Mentioned together
Goldman Sachs provides analysis and commentary on the performance and valuation of the Biotech sector.
-
ImmunityBio Shared context
ImmunityBio's performance is described as being tied to the overall performance of the Biotech sector.
-
Sarepta Shared context
Sarepta operates within the Biotech sector, and its performance is observed relative to the sector's market conditions.
-
Moderna Shared context
Moderna is identified as a leading company operating within the Biotech sector.
-
Congress Structural
Biotech is subject to formal regulation by Congress, which is considering changes to patent rights.
-
Amgen Mentioned together
Amgen is classified and listed within the broader Biotech sector.
-
Incyte Mentioned together
Biotech is mentioned in the M&A context of Incyte.
-
Gilead Sciences Mentioned together
Gilead Sciences is cited as a member of the Biotech sector.
-
Nasdaq Shared context
Biotech companies operate within the market structure provided by Nasdaq, which serves as a major listing exchange.
-
AbbVie Shared context
AbbVie is identified as a company operating within the Biotech sector.
-
Bangladesh Mentioned together
The relationship is observed in the context of general industry skepticism regarding AI.
-
London Shared context
Past failures in London influenced the sector prejudice of the Biotech industry.
-
Halozyme Therapeutics Mentioned together
Halozyme Therapeutics is classified as a biopharma technology platform company, placing it within the broader biotech sector.
-
Barry Callebaut Mentioned together
The evidence establishes that companies like Barry Callebaut are attracted to cultivated coffee, but does not define a specific relationship between Biotech and Barry Callebaut.
-
FED Mentioned together
The provided evidence focuses solely on the FED's response to inflation and tariffs, showing no direct coupling or relationship with Biotech.
-
Sioux Falls Mentioned together
The provided evidence does not contain any information linking Biotech to Sioux Falls.
-
Arabica Mentioned together
no direct coupling
History
Events by the month they beganOctober 2026
2 eventsAugust 2026
1 eventJuly 2026
3 events- The biotech sector relies on market infrastructure for raising capital.
- Amgen is classified as biotech for legacy reasons, a classification influenced by past failures experienced in London.
- The SEC legally requires fiduciaries to prioritize client interests, while specific ETFs like XBI offer equal-weighted exposure to biotech and hedge against AI concentration risk.
Show 1 earlier month
June 2026
4 events- M&A activity is driving sector recovery.
- Structure Therapeutics is an early-stage business operating within the biotech sector.
- Gains in Big Tech shares fueled market rise, while biotech company Enveda reached a billion-dollar valuation and a new international equity ETF was launched.
- EIT Food is discussing the shift towards biotech-driven approaches to address climate change impacts on Arabica coffee yields.